

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

For the Month of June 2018

1-15240
(Commission File Number)

JAMES HARDIE INDUSTRIES plc
(Translation of registrant's name into English)

Europa House, Second Floor
Harcourt Centre
Harcourt Street, Dublin 2, Ireland
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F..X.... Form 40-F.....

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Not Applicable

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Not Applicable

TABLE OF CONTENTS

Forward Looking Statements	3
Exhibit Index	5
Signatures	6

Forward-Looking Statements

This Form 6-K contains forward-looking statements. The Company may from time to time make forward-looking statements in its periodic reports filed with or furnished to the Securities and Exchange Commission, on Forms 20-F and 6-K, in its annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by the Company's officers, directors or employees to analysts, institutional investors, existing and potential lenders, representatives of the media and others. Statements that are not historical facts are forward-looking statements and such forward-looking statements are statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Examples of forward-looking statements include:

- statements about the Company's future performance;
- projections of the Company's results of operations or financial condition;
- statements regarding the Company's plans, objectives or goals, including those relating to strategies, initiatives, competition, acquisitions, dispositions and/or its products;
- expectations concerning the costs associated with the suspension or closure of operations at any of the Company's plants and future plans with respect to any such plants;
- expectations concerning the costs associated with the significant capital expenditure projects at any of the Company's plants and future plans with respect to any such projects;
- expectations regarding the extension or renewal of the Company's credit facilities including changes to terms, covenants or ratios;
- expectations concerning dividend payments and share buy-backs;
- statements concerning the Company's corporate and tax domiciles and structures and potential changes to them, including potential tax charges;
- statements regarding tax liabilities and related audits, reviews and proceedings;
- statements regarding the possible consequences and/or potential outcome of legal proceedings brought against us and the potential liabilities, if any, associated with such proceedings;
- expectations about the timing and amount of contributions to Asbestos Injuries Compensation Fund (AICF), a special purpose fund for the compensation of proven Australian asbestos-related personal injury and death claims;
- expectations concerning the adequacy of the Company's warranty provisions and estimates for future warranty-related costs;
- statements regarding the Company's ability to manage legal and regulatory matters (including but not limited to product liability, environmental, intellectual property and competition law matters) and to resolve any such pending legal and regulatory matters within current estimates and in anticipation of certain third-party recoveries; and
- statements about economic conditions, such as changes in the US economic or housing recovery or changes in the market conditions in the Asia Pacific region, the levels of new home construction and home renovations, unemployment levels, changes in consumer income, changes or stability in housing values, the availability of mortgages and other financing, mortgage and other interest rates, housing affordability and supply, the levels of foreclosures and home resales, currency exchange rates, and builder and consumer confidence.

Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "forecast," "guideline," "aim," "will," "should," "likely," "continue," "may," "objective," "outlook" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Readers are cautioned not to place undue reliance on these forward-looking statements and all such forward-looking statements are qualified in their entirety by reference to the following cautionary statements.

Forward-looking statements are based on the Company's current expectations, estimates and assumptions and because forward-looking statements address future results, events and conditions, they, by their very nature, involve inherent risks and uncertainties, many of which are unforeseeable and beyond the Company's control. Such known and unknown risks, uncertainties and other factors may cause actual results, performance or other achievements to differ materially from the anticipated results, performance or achievements expressed, projected or implied by these forward-looking statements. These factors, some of which are discussed under "Risk Factors" in Section 3 of the Form 20-F filed with the Securities and Exchange Commission on 22 May 2018, include, but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former Company subsidiaries; required contributions to AICF, any shortfall in AICF and the effect of currency exchange rate movements on the amount recorded in the Company's financial statements as an asbestos liability; the continuation or termination of the governmental loan facility to AICF; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which the Company operates; the consequences of product failures or defects; exposure to environmental, asbestos, putative consumer class action or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; possible increases in competition and the potential that competitors could copy the Company's products; reliance on a small number of customers; a customer's inability to pay; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; currency exchange risks; dependence on customer preference and the concentration of the Company's customer base on large format retail customers, distributors and dealers; dependence on residential and commercial construction markets; the effect of adverse changes in climate or weather patterns; possible inability to renew credit facilities on terms favorable to the Company, or at all; acquisition or sale of

businesses and business segments; changes in the Company's key management personnel; inherent limitations on internal controls; use of accounting estimates; integration of Fermacell into our business; and all other risks identified in the Company's reports filed with Australian, Irish and US securities regulatory agencies and exchanges (as appropriate). The Company cautions you that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those referenced in the Company's forward-looking statements. Forward-looking statements speak only as of the date they are made and are statements of the Company's current expectations concerning future results, events and conditions. The Company assumes no obligation to update any forward looking statements or information except as required by law.

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1</u>	Investor Roadshow Presentation - June 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 7 June 2018

James Hardie Industries plc

By: /s/ Natasha Mercer

Natasha Mercer

Company Secretary

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Investor Roadshow Presentation - June 2018

Exhibit 99.1



INVESTOR PRESENTATION

June 2018

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

This Management Presentation contains forward-looking statements. James Hardie Industries plc (the "Company") may from time to time make forward-looking statements in its periodic reports filed with or furnished to the Securities and Exchange Commission, on Forms 20-F and 6-K, in its annual reports to shareholders, in offering circulars, invitation memoranda and prospectuses, in media releases and other written materials and in oral statements made by the Company's officers, directors or employees to analysts, institutional investors, existing and potential lenders, representatives of the media and others. Statements that are not historical facts are forward-looking statements and such forward-looking statements are statements made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Examples of forward-looking statements include:

- statements about the Company's future performance;
- projections of the Company's results of operations or financial condition;
- statements regarding the Company's plans, objectives or goals, including those relating to strategies, initiatives, competition, acquisitions, dispositions and/or its products;
- expectations concerning the costs associated with the suspension or closure of operations at any of the Company's plants and future plans with respect to any such plants;
- expectations concerning the costs associated with the significant capital expenditure projects at any of the Company's plants and future plans with respect to any such projects;
- expectations regarding the extension or renewal of the Company's credit facilities including changes to terms, covenants or ratios;
- expectations concerning dividend payments and share buy-backs;
- statements concerning the Company's corporate and tax domiciles and structures and potential changes to them, including potential tax charges;
- statements regarding tax liabilities and related audits, reviews and proceedings;
- statements regarding the possible consequences and/or potential outcome of legal proceedings brought against us and the potential liabilities, if any, associated with such proceedings;
- expectations about the timing and amount of contributions to Asbestos Injuries Compensation Fund (AICF), a special purpose fund for the compensation of proven Australian asbestos-related personal injury and death claims;
- expectations concerning the adequacy of the Company's warranty provisions and estimates for future warranty-related costs;
- statements regarding the Company's ability to manage legal and regulatory matters (including but not limited to product liability, environmental, intellectual property and competition law matters) and to resolve any such pending legal and regulatory matters within current estimates and in anticipation of certain third-party recoveries; and
- statements about economic conditions, such as changes in the US economic or housing recovery or changes in the market conditions in the Asia Pacific region, the levels of new home construction and home renovations, unemployment levels, changes in consumer income, changes or stability in housing values, the availability of mortgages and other financing, mortgage and other interest rates, housing affordability and supply, the levels of foreclosures and home resales, currency exchange rates, and builder and consumer confidence.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS (continued)

Words such as "believe," "anticipate," "plan," "expect," "intend," "target," "estimate," "project," "predict," "forecast," "guideline," "aim," "will," "should," "likely," "continue," "may," "objective," "outlook" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Readers are cautioned not to place undue reliance on these forward-looking statements and all such forward-looking statements are qualified in their entirety by reference to the following cautionary statements.

Forward-looking statements are based on the Company's current expectations, estimates and assumptions and because forward-looking statements address future results, events and conditions, they, by their very nature, involve inherent risks and uncertainties, many of which are unforeseeable and beyond the Company's control. Such known and unknown risks, uncertainties and other factors may cause actual results, performance or other achievements to differ materially from the anticipated results, performance or achievements expressed, projected or implied by these forward-looking statements. These factors, some of which are discussed under "Risk Factors" in Section 3 of the Form 20-F filed with the Securities and Exchange Commission on 22 May 2018, include, but are not limited to: all matters relating to or arising out of the prior manufacture of products that contained asbestos by current and former Company subsidiaries; required contributions to AICF, any shortfall in AICF and the effect of currency exchange rate movements on the amount recorded in the Company's financial statements as an asbestos liability; the continuation or termination of the governmental loan facility to AICF; compliance with and changes in tax laws and treatments; competition and product pricing in the markets in which the Company operates; the consequences of product failures or defects; exposure to environmental, asbestos, putative consumer class action or other legal proceedings; general economic and market conditions; the supply and cost of raw materials; possible increases in competition and the potential that competitors could copy the Company's products; reliance on a small number of customers; a customer's inability to pay; compliance with and changes in environmental and health and safety laws; risks of conducting business internationally; compliance with and changes in laws and regulations; currency exchange risks; dependence on customer preference and the concentration of the Company's customer base on large format retail customers, distributors and dealers; dependence on residential and commercial construction markets; the effect of adverse changes in climate or weather patterns; possible inability to renew credit facilities on terms favorable to the Company, or at all; acquisition or sale of businesses and business segments; changes in the Company's key management personnel; inherent limitations on internal controls; use of accounting estimates; the integration of Fermacell into our business; and all other risks identified in the Company's reports filed with Australian, Irish and US securities regulatory agencies and exchanges (as appropriate). The Company cautions you that the foregoing list of factors is not exhaustive and that other risks and uncertainties may cause actual results to differ materially from those referenced in the Company's forward-looking statements. Forward-looking statements speak only as of the date they are made and are statements of the Company's current expectations concerning future results, events and conditions. The Company assumes no obligation to update any forward-looking statements or information except as required by law.

USE OF NON-GAAP FINANCIAL INFORMATION; AUSTRALIAN EQUIVALENT TERMINOLOGY

This Management Presentation includes financial measures that are not considered a measure of financial performance under generally accepted accounting principles in the United States (US GAAP). These financial measures are designed to provide investors with an alternative method for assessing our performance from on-going operations, capital efficiency and profit generation. Management uses these financial measures for the same purposes. These financial measures include:

- Adjusted EBIT;
- Adjusted EBIT margin;
- Adjusted net operating profit;
- Adjusted diluted earnings per share;
- Adjusted operating profit before income taxes;
- Adjusted income tax expense;
- Adjusted effective tax rate;
- Adjusted EBITDA;
- Adjusted EBITDA excluding Asbestos;
- Adjusted selling, general and administrative expenses ("Adjusted SG&A"); and
- Adjusted Return on Capital Employed ("Adjusted ROCE").

These financial measures are or may be non-US GAAP financial measures as defined in the rules of the U.S. Securities and Exchange Commission and may exclude or include amounts that are included or excluded, as applicable, in the calculation of the most directly comparable financial measures calculated in accordance with US GAAP. These non-GAAP financial measures should not be considered to be more meaningful than the equivalent US GAAP measure. Management has included such measures to provide investors with an alternative method for assessing its operating results in a manner that is focused on the performance of its ongoing operations and excludes the impact of certain legacy items, such as asbestos adjustments. Additionally, management uses such non-GAAP financial measures for the same purposes. However, these non-GAAP financial measures are not prepared in accordance with US GAAP, may not be reported by all of the Company's competitors and may not be directly comparable to similarly titled measures of the Company's competitors due to potential differences in the exact method of calculation. For additional information regarding the non-GAAP financial measures presented in this Management Presentation, including a reconciliation of each non-GAAP financial measure to the equivalent US GAAP measure, see the slide titled "Non-US GAAP Financial Measures" included in the Appendix to this Management Presentation.

In addition, this Management Presentation includes financial measures and descriptions that are considered to not be in accordance with US GAAP, but which are consistent with financial measures reported by Australian companies, such as operating profit, EBIT and EBIT margin. Since the Company prepares its Consolidated Financial Statements in accordance with US GAAP, the Company provides investors with a table and definitions presenting cross-references between each US GAAP financial measure used in the Company's Condensed Consolidated Financial Statements to the equivalent non-US GAAP financial measure used in this Management Presentation. See the section titled "Non-US GAAP Financial Measures" included in the Appendix to this Management Presentation.

AGENDA

- Global Overview
- North America Fiber Cement
- International Fiber Cement
- Corporate
- Appendix



GLOBAL OVERVIEW

OUR STRATEGIC FOCUS



PEOPLE

Continue to invest in the safety, development and promotion of our people



BRAND PROMISE

Build on industry leadership through unrivaled commitment to manufacturing, R&D, technology and capacity planning

DRIVING
PROFITABLE
GROWTH
DELIVERING
SUPERIOR
RETURNS



MARKET POSITION

Grow fiber cement market share in all geographies we operate in



NON-FIBER CEMENT

Develop other streams of growth beyond fiber cement


A GROWTH FOCUSED COMPANY



- Annual net sales US\$2.1b
- Total assets US\$2.4b
- Strong operational cash generation
- Operations in North America, Asia Pacific and Europe
- 3,960 employees
- Market cap US\$7.5b
- S&P/ASX 100 company
- NYSE ADR listing

Market capitalization per Bloomberg as at 31 May 2018. Total assets and total average employees for the year ended 31 March 2018. Annual net sales is for the twelve months ended 31 March 2018.

WORLD LEADER IN FIBER CEMENT



KEY
■ North America Fiber Cement
■ International Fiber Cement
▲ Research & Development
● Manufacturing Facilities

Geographic Mix¹

Net Sales



EBIT²




¹ All percentages are for the fiscal year ended 31 March 2018

² EBIT – excludes research and development, asbestos-related expenses and adjustments and Fermacell acquisition costs

BUILDING A PORTFOLIO OF PRODUCTS AND BRANDS

Primary Products



Brand Portfolio




CREATING A SUSTAINABLE AND DIFFERENTIATED ADVANTAGE

Research & Development: Significant and consistent investment

- US\$27.8m spent on Research & Development in FY18
- US\$521.7m spent on Research & Development since 2000



History of Fiber Cement Substrate Development



DELIVERING SUPERIOR PRODUCT PERFORMANCE


Fiber cement is more durable than wood and engineered wood, looks and performs better than vinyl, and is more cost effective and quicker to build with than brick

Fiber Cement



- ✓ Fire resistant ?
- ✓ Hail resistant ?
- ✓ Resists warping ?
- ✓ Resists buckling ?
- ✓ Lasting color ?
- ✓ Dimensional stability ?
- ✓ Can be repainted ?

Vinyl




- ?
- ?
- ?
- ?
- ?
- ?
- ?

Engineered Wood



GLOBAL FINANCIALS


Adjusted Net Operating Profit¹ (US\$m)



Net Sales (US\$m)



Adjusted Diluted Earnings Per Share¹ (US cents)



Adjusted EBIT² (US\$m)




¹ Excludes asbestos-related expenses and adjustments, asset impairments, ASIC expenses, New Zealand weathertightness claims, tax adjustments, loss on early debt extinguishment and Fermacell acquisition costs. ² Excludes asbestos-related expenses and adjustments and Fermacell acquisition costs



NORTH AMERICA FIBER CEMENT

DRIVING CATEGORY AND MARKET SHARE GAINS

North America External Cladding Share¹



35/90 Plan


- Grow fiber cement share to 35% of the exterior cladding market against other wood-looking siding alternatives
- Maintain JHX's category share at 90%

Currently:

- JHX wins ~90% of the fiber cement category, while fiber cement used in ~19% of the total market
- Current estimate is wood-look siding (Wood, Vinyl and Fiber Cement) is 65-70% of total market.

¹Source: Internal estimates based on NAHB product usage data adjusted for regional market intelligence

NORTH AMERICA FIBER CEMENT SEGMENT



- Largest fiber cement producer in North America
- 2,659 employees¹
- 9 manufacturing plants
- 2 research and development facilities
- Annual flat sheet design capacity 3,744 mmsf² as at 31 March 2018

¹ Total average employees for the year ended 31 March 2018


² The annual design capacity does not necessarily reflect the actual capacity utilization rates of our manufacturing facilities, with actual utilization affected by factors such as demand, product mix, batch size, plant availability and production speeds. For further information please refer to the Form 20-F filed with the Securities and Exchange Commission on 22 May 2018.

AGGRESSIVELY GROWING DEMAND FOR OUR PRODUCTS


Top Line Growth¹



Average Net Sales Price (US\$ per MSF)



Quarterly EBIT and EBIT Margin²



¹ Rolling 12 month average of seasonally adjusted estimate of housing starts by US Census Bureau


² Excludes asset impairment charges of US\$5.8 million in Q3 FY13 and US\$11.1 million in Q4 FY13



INTERNATIONAL FIBER CEMENT

INTERNATIONAL DELIVERING STRONG RETURNS

Quarterly EBIT and EBIT Margin¹



5 year results

	FY14	FY15	FY16	FY17	FY18
Net Sales US\$m	399	418	379	412	462
Sales Volume mmsf	441	484	481	487	529
EBIT US\$m ¹	86	90	78	95	108
EBIT Margin % ¹	22	22	21	23	24



¹ EBIT and EBIT margin excludes New Zealand weathertightness claims

INTERNATIONAL FIBER CEMENT SEGMENT



- 1,050 employees¹
- 4 manufacturing plants
- 1 research and development facility
- Annual flat sheet design capacity 600 mmsf² as at 31 March 2018
- Additional capacity is being added in the Philippines and Carole Park




¹ Total average employees for the year ended 31 March 2018

² The annual design capacity does not necessarily reflect the actual capacity utilization rates of our manufacturing facilities, with actual utilization affected by factors such as demand, product mix, batch size, plant availability and production speeds. For further information please refer to the Form 20-F filed with the Securities and Exchange Commission on 22 May 2018.




FERMACELL ACQUISITION

EUROPE OVERVIEW

	Before Acquisition 		Post Acquisition 
Workforce	• 70 employees		• 900+ employees 
Presence	• UK, FR, DK, DE		• 12+ countries • 5 manufacturing facilities
Segments	• Residential New Construction • Repair and Renovation		• Residential New Construction • Repair and Renovation • Commercial
Products	• Fiber Cement	 	• Fiber Cement • Fiber Gypsum • Cement Bonded
Revenue¹	• € 31 M		• ~ € 300 M

¹ 'Before Acquisition' revenue is based on unaudited James Hardie Europe financial records for 12 months ended 31 March 2018. 'Post Acquisition' revenue is a 12 month estimate based on unaudited James Hardie Europe financial records and unaudited Fermacell IFRS financial records for the 12 months ended 31 March 2018.

EUROPE FINANCIALS AND FUTURE GROWTH



FY 18 Financials¹

- JH Europe Revenue ~ € 300 million
- JH Europe EBIT margin ~10%

Future Growth

- Fiber Gypsum
- Existing Fiber Cement Products
- New Fiber Cement Product Development

Other Data

- Fermacell Historical revenue growth
 - 3 year CAGR ~5%
- Estimated integration costs in FY19
 - ~ € 20 million

¹ FY18 financial estimates are based on unaudited James Hardie Europe financial records for the twelve months ended 31 March 2018 and unaudited Fermacell IFRS financial records for the 12 months ended 31 March 2018.



CORPORATE



FINANCIAL MANAGEMENT SUPPORTING GROWTH

Strong Financial Management

- Strong margins and operating cash flows
- Strong governance and transparency
- Investment-grade financial management

Disciplined Capital Allocation

- Invest in R&D and capacity expansion to support organic growth
- Maintain ordinary dividends within the defined payout ratio
- Flexibility for:
 - Cyclical market volatility
 - Accretive and strategic inorganic opportunities
 - Further shareholder returns when appropriate

Liquidity and Funding

- Conservative leveraging of balance sheet at a target within 1-2 times Adjusted EBITDA excluding asbestos.
 - US\$500 million of unsecured revolving credit facility; US\$800 million senior unsecured notes at Q4 FY18
 - Weighted average maturity of 4.7 years on bank debt; 6.9 years on total debt at Q4 FY18
 - On 3 April 2018, drew €400m on our bridge finance to fund Fermacell acquisition

Moody's

S&P

Fitch

Ba1

affirmed Nov'17
outlook stable

BB

affirmed Nov'17
outlook stable

BBB-

affirmed Nov'17
outlook stable

Financial management consistent with investment grade credit
Ability to withstand market cycles and other unanticipated events

FY2019 KEY PLANNING ASSUMPTIONS

- The Company expects to see steady growth in the US housing market continue in fiscal year 2019
- US Residential Housing Starts forecasted to be between 1.2 and 1.3 million
- North America Fiber Cement Segment
 - EBIT margins expected to be in the top end of our stated target range of 20% to 25%
 - Expectation is based upon the Company continuing to deliver operating performance in our plants consistent with recent quarters, stable exchange rates and a moderate inflationary trend for input costs
- Australian business expected to trend in line with the average growth of the domestic repair and remodel and single detached housing markets in the eastern states of Australia
- Macroeconomic and housing market conditions in the European markets consistent with fiscal year 2018

APPENDIX

NON-US GAAP FINANCIAL MEASURES AND TERMS

This Management Presentation forms part of a package of information about the company's results. It should be read in conjunction with the other parts of this package, including the Management's Analysis of Results, Media Release and Consolidated Financial Statements

Definitions

EBIT – Earnings before interest and taxes

EBIT margin – EBIT margin is defined as EBIT as a percentage of net sales

Sales Volumes

mmsf – million square feet, where a square foot is defined as a standard square foot of 5/16" thickness

msf – thousand square feet, where a square foot is defined as a standard square foot of 5/16" thickness

Non-financial Terms

AFFA – Amended and Restated Final Funding Agreement

AICF – Asbestos Injuries Compensation Fund Ltd

NON-US GAAP FINANCIAL MEASURES

Financial Measures – US GAAP equivalents

This document contains financial statement line item descriptions that are considered to be non-US GAAP, but are consistent with those used by Australian companies. Because the company prepares its Consolidated Financial Statements under US GAAP, the following table cross-references each non-US GAAP line item description, as used in Management's Analysis of Results and Media Release, to the equivalent US GAAP financial statement line item description used in the company's Consolidated Financial Statements:

Management's Analysis of Results and Media Release	Consolidated Statements of Operations and Other Comprehensive Income (Loss) (US GAAP)
Net sales	Net sales
Cost of goods sold	Cost of goods sold
Gross profit	Gross profit
Selling, general and administrative expenses	Selling, general and administrative expenses
Research and development expenses	Research and development expenses
Asbestos adjustments	Asbestos adjustments
EBIT*	Operating income (loss)
Net interest income (expense)*	Sum of interest expense and interest income
Other income (expense)	Other income (expense)
Operating profit (loss) before income taxes*	Income (loss) before income taxes
Income tax (expense) benefit	Income tax (expense) benefit
Net operating profit (loss)*	Net income (loss)

*- Represents non-US GAAP descriptions used by Australian companies.

NON-US GAAP FINANCIAL MEASURES

Financial Measures – US GAAP equivalents

Adjusted EBIT

US\$ Millions	Three Months and Full Year Ended 31 March			
	Q4'18	Q4'17	FY18	FY17
EBIT	\$ (95.8)	\$ 78.2	\$ 229.2	\$ 393.2
Asbestos:				
Asbestos adjustments	192.9	(1.4)	156.4	(40.4)
AICF SG&A expenses	0.6	0.3	1.9	1.5
Farmacell acquisition costs	5.3	-	10.0	-
Adjusted EBIT	\$ 103.0	\$ 77.1	\$ 397.5	\$ 354.3
Net sales	\$ 525.9	\$ 494.3	\$ 2,054.5	\$ 1,921.6
Adjusted EBIT margin	19.6%	15.6%	19.3%	18.4%

Adjusted net operating profit

US\$ Millions	Three Months and Full Year Ended 31 March			
	Q4'18	Q4'17	FY18	FY17
Net operating (loss) profit	\$ (57.6)	\$ 44.5	\$ 146.1	\$ 276.5
Asbestos:				
Asbestos adjustments	192.9	(1.4)	156.4	(40.4)
AICF SG&A expenses	0.6	0.3	1.9	1.5
AICF interest (income) expense, net	(0.9)	0.3	(1.9)	1.1
Loss on early debt extinguishment	-	-	26.1	-
Farmacell acquisition costs	5.3	-	10.0	-
Tax adjustments ¹	(59.2)	10.9	(47.3)	9.9
Adjusted net operating profit	\$ 81.1	\$ 54.6	\$ 291.3	\$ 248.6

¹ Includes tax adjustments related to Asbestos, loss on early debt extinguishment and other tax adjustments

NON-US GAAP FINANCIAL MEASURES

Adjusted diluted earnings per share

	Three Months and Full Year Ended 31 March			
	Q4'18	Q4'17	FY18	FY17
Adjusted net operating profit (US\$ Millions)	\$ 81.1	\$ 54.6	\$ 291.3	\$ 248.6
Weighted average common shares outstanding - Diluted (millions)	443.0	441.4	442.3	443.9
Adjusted diluted earnings per share (US cents)	18	12	66	56

Adjusted effective tax rate

US\$ Millions	Three Months and Full Year Ended 31 March			
	Q4'18	Q4'17	FY18	FY17
Operating (loss) profit before income taxes	\$ (103.2)	\$ 71.1	\$ 174.3	\$ 367.0
Asbestos:				
Asbestos adjustments	192.9	(1.4)	156.4	(40.4)
AICF SG&A expenses	0.6	0.3	1.9	1.5
AICF interest (income) expense, net	(0.9)	0.3	(1.9)	1.1
Loss on early debt extinguishment	-	-	26.1	-
Fermacell acquisition costs	5.3	-	10.0	-
Adjusted operating profit before income taxes	\$ 94.7	\$ 70.3	\$ 366.8	\$ 329.2
Income tax benefit (expense)	\$ 45.6	\$ (26.6)	\$ (28.2)	\$ (90.5)
Tax adjustments ¹	(59.2)	10.9	(47.3)	9.9
Adjusted income tax expense	\$ (13.6)	\$ (15.7)	\$ (75.5)	\$ (80.6)
Effective tax rate	44.2%	37.4%	16.2%	24.7%
Adjusted effective tax rate	14.4%	22.3%	20.6%	24.5%

¹ Includes tax adjustments related to Asbestos, loss on early debt extinguishment and other tax adjustments

NON-US GAAP FINANCIAL MEASURES

Adjusted EBITDA excluding Asbestos

US\$ Millions	Three Months and Full Year Ended 31 March			
	Q4'18	Q4'17	FY18	FY17
EBIT	\$ (95.8)	\$ 78.2	\$ 229.2	\$ 393.2
Depreciation and amortization	23.4	20.7	92.0	83.2
Adjusted EBITDA	\$ (72.4)	\$ 98.9	\$ 321.2	\$ 476.4
Asbestos:				
Asbestos adjustments	192.9	(1.4)	156.4	(40.4)
AICF SG&A expenses	0.6	0.3	1.9	1.5
Adjusted EBITDA excluding Asbestos	\$ 121.1	\$ 97.8	\$ 479.5	\$ 437.5

Adjusted selling, general and administrative expenses ("Adjusted SG&A")

US\$ Millions	Three Months and Full Year Ended 31 March			
	Q4'18	Q4'17	FY18	FY17
SG&A expenses	\$ 85.1	\$ 75.9	\$ 311.3	\$ 291.6
Excluding:				
AICF SG&A expenses	(0.6)	(0.3)	(1.9)	(1.5)
Fermacell acquisition costs	(5.3)	-	(10.0)	-
Adjusted SG&A expenses	\$ 79.2	\$ 75.6	\$ 299.4	\$ 290.1
Net sales	\$ 525.9	\$ 494.3	\$ 2,054.5	\$ 1,921.6
SG&A expenses as a percentage of net sales	16.2%	15.4%	15.2%	15.2%
Adjusted SG&A expenses as a percentage of net sales	15.1%	15.3%	14.6%	15.1%

NON-US GAAP FINANCIAL MEASURES

Adjusted Return on Capital Employed ("Adjusted ROCE")

US\$ Millions	Full Year Ended 31 March ¹	
	FY18	FY17
Numerator		
Adjusted EBIT	\$ 397.5	\$ 354.3
Denominator		
Gross capital employed (GCE)	1,272.0	1,107.6
Adjustment to GCE	(24.3)	50.3
Adjusted gross capital employed	\$ 1,247.7	\$ 1,157.9
Adjusted Return on Capital Employed	31.9%	30.6%

¹ Adjusted ROCE is used to assess annual financial results and therefore is not presented for the three months ended 31 March 2018



INVESTOR PRESENTATION

June 2018
